American Journal of Hematology

Article	Citations
Clonal hematopoiesis in unexplained cytopenias	441
Deciphering clonal architecture and evolutionary dynamics of secondary acute myeloid leukemia and donor‐derived myelodysplastic syndrome using single‐cell multi‐omics analysis	252
	211
The latest insights into rare blood disorders: Diagnosis and treatment strategies	152
Comparative thrombotic risk associated with CALR1, CALR2, and JAK2 V617F mutations in essential thrombocythemia	146
Complete response to pembrolizumab and radiation in a patient with HIV‐negative, EBV‐positive plasmablastic lymphoma	142
Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data	135
Issue Information	133
NPM1‐mutated myeloid neoplasm with low percentage of blasts	128
Improving healthspan among people with sickle cell disease: Leveraging precision health in an era of treatments with curative intent	121
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations	106
Unveiling the genetic landscape of suspected congenital dyserythropoietic anemia type I: A retrospective cohort study of 36 patients	92
Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?	83
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis	78
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives	75
A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia	75
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis	69
Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era	68
Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion	67
The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors	65
How the United States syphilis epidemic may portend a resurgence of an unusual hematologic condition: The connection between syphilis and paroxysmal cold hemoglobinuria	64
Sustained, complete response to pexidartinib in a patient with CSF1R‐mutated Erdheim–Chester disease	62
Characteristics and prevalence of antibiotic allergies in patients with sickle cell disease: A single‐center retrospective study	62
Tocilizumab for severe acute chest syndrome in a child with sickle cell disease and dramatically high interleukin‐6 values in endotracheal and pleural fluids	59
	59

Oligoclonal gamma‐delta T cell expansion in response to Ehrlichia infection	56
Breast implant‐associated anaplastic large cell lymphoma	56
Multi‐organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease	56
Acute thrombocytopenia suggesting thrombotic microangiopathy	55
A t(6;14;9)(p22;q22;q34) three‐way translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia	55
An unusual lymphoma involving the GI tract and bone marrow	55
Hemolysis after high‐dose intravenous immunoglobulin: An under‐appreciated sequelae	53
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome	52
Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications	48
Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes fr	47
Clinically meaningful improvements in patient‐reported outcomes in mitapivat‐treated patients with pyruvate kinase deficiency	46
Issue Information	45
Novel germline JAK2R715T mutation causing PV‐like erythrocytosis in 3 generations. Amelioration by Ropeg‐Interferon	45
Normal B cells express ZAP70 in chronic lymphocytic leukemia: A link between autoimmunity and lymphoproliferation?	44
Clinical impact of cytomorphology in mast cell leukemia	44
Rainer Prohaska (1943–2022)	44
Sickle cell allele HBB‐rs334(T) is associated with decreased risk of childhood Burkitt lymphoma in East Africa	43
Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies	42
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma	42
Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity‐score matched analysis	41
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity	41
A population‐based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single i	40
Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo‐controlled study (IRON	37
Treatment Effectiveness of Venetoclax‐Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real‐World Study	37
Primary Effusion Lymphoma Prognostic Score (PEL‐PS): A Validated International Prognostic Score in HIV‐Associated Primary Effusion Lymphoma	37
Hyper‐CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome‐Negative B‐Cell Acute Lymphoblastic Leukemia	36
Drug‐induced hypersensitivity syndrome and eosinophils in skin biopsy in a patient with pancytopenia	36
	36
Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International	36
Risk Factors and Prognostic Markers for Posterior Reversible Encephalopathy Syndrome in Patients With Thalassemia Major After Allogeneic Hematopoietic Stem Cell Transplantation	36
Immune cell kinetics and antibody response in COVID‐19 patients with low‐count monoclonal B‐cell lymphocytosis	35
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia	35
Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: Assessment of different risk scores	34
Acute Epstein‐Barr virus associated haemophagocytosis in an Asian female: What is the diagnosis?	34
Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization	34
Muscular de‐conditioning and reduced cardiac inotropism due to iron deposition reduce exercise tolerance in beta thalassemia major	34
Granular Mott cells in multiple myeloma	34
Diagnosis of histiocytic sarcoma by bone marrow aspiration	33
Occult recurrent breast cancer masquerading as thrombotic thrombocytopenic purpura	33
Issue Information	33
Clonal hematopoiesis in patients with Covid‐19 is stable and not linked to an aggravated clinical course	32
Antibody response to COVID‐19 mRNA vaccine (Comirnaty) in myeloma patients treated with high‐dose melphalan and/or immunotherapy	31
Fetal hemoglobin per erythrocyte (HbF/F‐cell) after gene therapy for sickle cell anemia	31
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms	30
Issue Information	30
Patient‐reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease	30
Pretreatment clinical and genetic factors predict early post‐treatment mortality in fit AML patients following induction	30
Long‐term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T‐cells	30
Megakaryocyte morphology with GATA2 germline mutation	29
Hemolytic crisis due to Covid‐19 vaccination in a woman with cold agglutinin disease	29

Erythropoietin‐secreting metanephric adenoma presenting as erythrocytosis	29
Is ≥ 100% the magic number to rule out the laboratory diagnosis of von Willebrand disease based on initial testing?	29
Daratumumab monotherapy for relapsed POEMS syndrome	29
Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies	29
Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age	28
A newly identified ferritin L‐subunit variant results in increased proteasomal subunit degradation, impaired complex assembly, and severe hypoferritinemia	28
Increased transferrin protects from thrombosis in Chuvash erythrocytosis	28
Moving toward more molecular classifications of myelodysplastic syndrome and acute myeloid leukemia	27
Outcome prediction by the knowledge bank approach in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation	27
Bone marrow granulomatous reaction to silicone from breast implants	27
	27
Hematopoietic stem cell transplantation from haploidentical offspring donors using post‐transplant cyclophosphamide versus human leukocyte antigen‐matched siblings in older patients with myelodysplast	27
Issue Information	27
Hematological support of patients with significant anemia who decline red blood cell blood transfusion	27
Self‐pay laboratory charges for iron deficiency diagnosis in the Boston and New Haven metropolitan areas	26
Issue Information	26
Imatinib versus newer generation TKIs for upfront therapy in chronic phase chronic myeloid leukemia: What is the rationale for paying more to get the same survival benefit?	26
Is it time to reconsider molecular response milestones in chronic myeloid leukemia?	25
Severe SARS‐CoV‐2 infection in rituximab‐treated patients with autoimmune cytopenia: A multicenter observational study	25
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) and myelodysplastic s	25
Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real‐world registry study in Japan	25
Issue Information	25
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy	25
Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia	25
Unraveling the mystery of the spleen	25
The insertion site is the main risk factor for central venous catheter‐related complications in patients with hematologic malignancies	25
Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms	24
CD19‐negative relapse in adult patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia following treatment with blinatumomab‐a post hoc analysis	24
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management	24
Increased CD8 T‐cell immunity after COVID‐19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?	24
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate‐risk acute myeloid leukemia in first complete remission undergoing auto‐HSCT: An open‐label, mu	24
Unselected donor‐derived hematopoietic stem cells boost for Chimeric Antigen Receptor T‐cell associated hematotoxicity	24
Pseudoreticulocytosis in a patient with myelodysplastic syndrome	24
Increased blood reactive oxygen species and hepcidin in obstructive sleep apnea precludes expected erythrocytosis	24
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30‐year experience	24
BNT162b2 mRNA SARS‐CoV‐2 vaccination does not cause upregulation of endothelial activation markers or hypercoagulability: A prospective, single‐arm, longitudinal study	24
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers	24
Therapeutic Targeting of the Activin Receptor Signaling Pathway: Proof of Concept in Myeloid Neoplasms	24
Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia	24
Monotypic plasmacytoid cells mimicking lymph node malignancy in the setting of COVID‐19 recovery	24
Artificial intelligence generated leukemia cell images	24
Assessing hypercoagulability and VTE risk using thromboelastography and Khorana score in women with cancers receiving chemotherapy	23
Ruxolitinib for refractory large granular lymphocyte leukemia	23
Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon	22
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent	22
Long‐term risk of venous thromboembolism among patients with gastrointestinal non‐neoplastic and neoplastic diseases: A prospective cohort study of 484 211 individuals	22
A common pattern of somatic mutations in t‐MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer	22
Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transpl	22
Issue Information	22
Steady‐State Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity Predicts Low Platelet Count at Hospitalization for Sickle Cell Disease Vaso‐Occlusive Episodes	22
COVID‐19 mRNA vaccine‐associated cerebral venous thrombosis: Rare adverse event or coincidence?	22
Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients From the JIR Cohort	22
SARS‐CoV‐2 infection in patients with β‐thalassemia: Experience from Lebanon	22
TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins	22
Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis	21
Approach to a patient with “double refractory” chronic lymphocytic leukemia: “Double, double toil and trouble” (Shakespeare)	21
Extranodal natural killer/T‐cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets	21
Blood Plasma Methylated DNA Markers in the Detection of Lymphoma: Discovery, Validation, and Clinical Pilot	21
Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high‐ and low‐ to middle‐income countries for the i	21
Transcranial doppler velocity in iron‐deficient Nigerian children with sickle cell anemia	20
Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib	20
Hairy cell leukemia 2024: Update on diagnosis, risk‐stratification, and treatment—Annual updates in hematological malignancies	20
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study	20
Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel	20
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors	20
	20
Blastic Plasmocytoid Dendritic Cell Neoplasm With Pseudo‐Lymphoid Morphology Mimicking Lymphoid Malignancy	20
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients	19
An integrated therapeutic approach to sickle cell disease management beyond infancy	19
Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti‐spike neutralizing IgG to SARS‐CoV‐2 variants, but preserved antigen‐specific T cell	19
Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States	19
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA	19
Epidemiology of clinically significant forms of alpha‐ and beta‐thalassemia: A global map of evidence and gaps	19
Serum erythropoietin levels in 696 patients investigated for erythrocytosis with JAK2 mutation analysis	19
Adverse events reported to the U.S. Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel	19
Trial designs and endpoints for immune therapies in multiple myeloma	19
Kinetics of anti‐SARS‐CoV‐2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy	19
Peripheral blood cells vacuoles in VEXAS syndrome	19
Thrombopoietin mimetic‐induced bone marrow fibrosis	19
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study	19

Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia: Critical analysis of the ASC4FIRST trial	19
The cognitive age in medicine: Artificial intelligence, large language models, and iterative intelligence	18
The invisible lifeline: Intricacies of the global plasma supply	18
Age barriers in allogeneic hematopoietic cell transplantation: Raising the silver curtain	18
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A multi‐institutional study	18
Are veterans at increased risk of myeloproliferative neoplasms?	18
Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open‐label study	18
Pituitary apoplexy in acute promyelocytic leukemia	18
At what COST?: A prospective longitudinal cohort assessment of financial toxicity, quality of life, and associated risk factors in patients with plasma cell disorders	18
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma	17
Bispecific T‐cell engagers for treatment of multiple myeloma	17
The impact of sex on platelet responses to aspirin in patients with peripheral artery disease	17
Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation	17
Intranasal fentanyl works—Why are we not using it more to treat acute pain in sickle cell disease?	17
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma	17
Real‐world Big‐data: Strengths and weaknesses of ASCO's CancerLinQ® discovery multiple myeloma dataset	17
Alemtuzumab in relapsed immune severe aplastic anemia: Long‐term results of a phase II study	17
Evaluation of the clinical significance of global mRNA alternative splicing in patients with acute myeloid leukemia	17
The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases	17
Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping	16
Hereditary stomatocytosis in the general population: A genetically based prevalence estimate from a 109 039 individual Danish cohort	16
Pseudo‐Chédiak–Higashi anomaly in acute myeloid leukemia	16
Effect of voxelotor on cerebral perfusion and cerebral oxygen metabolism and cardiac stress in adult patients with sickle cell disease	16
SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell	16
The international consensus classification of myeloid neoplasms and acute leukemias: Myeloproliferative neoplasms	16
Cytopenias revealing a case of carcinocythemia with bone marrow metastasis	16
Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma: A multicenter, real‐world study in China	16
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML	16
CORRIGENDUM	16
An unusual form of BRAF‐V600E mutated hairy cell neoplasm with clinical resistance to BRAF inhibition: Challenging precision medicine	16
Endogenous retroelements in hematological malignancies: From epigenetic dysregulation to therapeutic targeting	16
Prognostic significance of early acute splenic sequestration in children with severe sickle cell genotypes: A comprehensive longitudinal neonatal cohort study	16
Multiple myeloma with central nervous system relapse presenting as right pupil‐sparing complete third nerve palsy	15
A matching‐adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia	15
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival	15
Follicular lymphoma: 2023 update on diagnosis and management	15
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative	15
Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab	15
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia	15
Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management	15
Making a virtue out of an evil: Are red blood cells from chronic mountain sickness patients eligible for transfusions?	15
CORRIGENDUM	15
Crushed deferasirox film‐coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single‐arm, interventional phase 4 study (MIMAS)	15
A framework for the clinical implementation of optical genome mapping in hematologic malignancies	15
Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications	15
Cyclophosphamide Abrogates Immune Effector Cell‐Associated Neurotoxicity Syndrome Associated With CAR‐T Cell Therapy	15
Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10−4 and higher	15
Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma	15
COVID‐19 vaccines and risks of hematological abnormalities: Nested case–control and self‐controlled case series study	15
Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients	15
Transdifferentiation of B‐lymphoblastic leukemia to histiocytic sarcoma after immunotherapy	15
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐BCMA CAR T‐cell‐based therapy	14
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management	14
Molecular and clinicopathologic characterization of pediatric histiocytoses	14
Multicenter Retrospective Evaluation of Treatment for High‐Risk Acute Promyelocytic Leukemia: Real‐World Outcomes From the HERO Consortium	14
Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery	14
A novel adoptive synthetic TCR and antigen receptor (STAR) T‐Cell therapy for B‐Cell acute lymphoblastic leukemia	14
R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study	14
The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception	14
Circulating rhabdoid tumor cells in the peripheral blood of a neonate	14
Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts	14
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia	14
Congenital X‐linked neutropenia with myelodysplasia and somatic tetraploidy due to a germline mutation in SEPT6	14
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castlema	14
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management	14
Single‐agent daratumumab for refractory POEMS syndrome	14
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment	14
Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis	14
Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis	14
Clinical characteristics of cytomegalovirus‐positive pediatric acute lymphoblastic leukemia at diagnosis	14
Long‐term effectiveness of eliglustat treatment: A real‐world analysis from the International Collaborative Gaucher Group Gaucher Registry	14
Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T‐Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle	14
Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management	13
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis	13
Biology and Management of Acute Myeloid Leukemia With Mutated NPM1	13
Recent advances in the pathophysiology of PIEZO1‐related hereditary xerocytosis	13
It's More Than Complex: Further Insights Into TP53 in MPN	13
Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study	13
NPM1‐mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions	13
Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐GemOx: A Multicenter Cohort Study	13
Teclistamab in patients with multiple myeloma and impaired renal function	13
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia	13
2021 update on clinical trials in β‐thalassemia	13
Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO t	13
Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy	13
Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management	13
World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management	13
Dosage of high‐dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse	13
Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)—A randomized, placebo‐controlled phase II feasibility/pilot study	13
Clinical events in a long‐term prospective neonatal cohort of children with sickle cell disease: Evidence for a high disease burden without systematic preventive intensification with hydroxyurea	13
Cardiac effects 2 years after successful non‐myeloablative human leukocyte antigen‐matched related donor hematopoietic cell transplants in sickle cell disease	12
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma	12
NOTCH1 Mutations Are Associated With Therapy‐Resistance in Patients With B‐Cell Lymphoma Treated With CD20xCD3 Bispecific Antibodies	12
Long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system	12
Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post‐transplant cyclophosphamide versus conventional anti‐graft versus host disease prophylaxis in patients with	12